Genome-wide shRNA screens showed neurotransmitter pathways, including the DRD2, are critical to the growth and survival of glioblastoma cell lines (in vitro and in vivo), highlighting the potential of ONC201/GsONC201, a known DRD2 antagonist.8,38–40 The pro-proliferative effects of DRD2 signaling in glioblastoma are mediated, in part, by Ras/ERK signaling, with the use of the antipsychotic haloperidol (FDA approved DRD2 antagonist), like ONC201, used in less sensitive DIPG cells, decreasing ERK activity while having no effect on Akt38 (Figure 2C). This evidence concerns the gene DRD2 and glioblastoma.